Who is sponsoring LIRAVIS?

LIRAVIS is sponsored by Yaounde Central Hospital.

What condition does LIRAVIS study?

LIRAVIS studies Type 2 Diabetes Mellitus.

What drugs are being tested in LIRAVIS?

Interventions: sub cutaneous liraglutide, Oral Vildagliptin.

What is the status of LIRAVIS?

LIRAVIS is currently COMPLETED.

Last reviewed 2017-12-21 · How we verify

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in a Sub Saharan African Population With Type 2 Diabetes (LIRAVIS)

NCT02832999 Phase 4 COMPLETED

This is a single blind randomised controlled clinical trial in uncontrolled type 2 Diabetes mellitus patients on oral glucose lowering agents, and naive to incretinomimetic. Participants will be randomised in two Arms : arm 1 receiving Liraglutide at 1,2 mg/day and arm 2 Vildagliptine at 100mg/day over 14 days. The two arms will be compared for 14-day changes in insulin secretion and insulin sensitivity.

Details

Lead sponsor	Yaounde Central Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	14
Start date	2016-01
Completion	2016-12

Conditions

Type 2 Diabetes Mellitus

Interventions

sub cutaneous liraglutide
Oral Vildagliptin

Primary outcomes

Insulin sentivity — 2 weeks
2-week change in clamp-measured insulin sensitivity

Countries

Cameroon